Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero®)

Journal of Infection

Volumn 69, Issue 5, 2014, Pages 470-480

  Ladhani, Shamez N ^a,b   Cordery, Rebecca ^a   Mandal, Sema ^a   Christensen, Hannah ^c   Campbell, Helen ^a   Borrow, Ray ^d   Ramsay, Mary E ^a   Earnshaw, Andrew ^e   Gorringe, Andrew ^f   Trotter, Caroline ^g   Cameron, Claire ^h   Wilson, Deborah ^f   Kaczmarski, Ed ^f   Hart, Judy ⁱ   Coole, Louise ^f   Maiden, Martin ^j   Slack, Mary ^f   Irvine, Neil ^k   Heath, Paul ^b   Waight, Pauline ^f   Monk, Philip ^f   Care, Rory ^l   Kroll, Simon ^m   Gray, Steve ^f   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c University of Bristol Canynge Hall   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e Department of Health ^*  (United Kingdom)

^f PHE Public Health England   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h HEALTH PROTECTION SCOTLAND   (United Kingdom)

ⁱ PUBLIC HEALTH WALES   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k Health Protection Service Northern Ireland   (United Kingdom)

^l NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Chemoprophylaxis; Contacts; Meningococcal B vaccine; Outbreaks; Prevention

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE;

ADOLESCENT; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CHILD; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; HEALTH EDUCATION; HIGH RISK POPULATION; HOUSEHOLD; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MENINGOCOCCAL CAPSULAR GROUP B DISEASE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; ONSET AGE; SCHOOL CHILD; SECONDARY INFECTION; SINGLE DRUG DOSE; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; NUMBERS NEEDED TO TREAT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NUMBERS NEEDED TO TREAT;

EID: 84908553399     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.002     Document Type: Article

References (29)

1. Health Protection Agency Guidance for public health management of meningococcal disease in the UK 2011, Available at:, [accessed 03.07.14]. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947389261.
2. Zangwill K.M., Schuchat A., Riedo F.X., Pinner R.W., Koo D.T., Reeves M.W., et al. School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JAMA 1997, 277(5):389-395.
3. Purcell B., Samuelsson S., Hahne S.J., Ehrhard I., Heuberger S., Camaroni I., et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ 2004, 328(7452):1339.
4. Samuelsson S. Surveillance and prevention of meningococcal disease in Denmark 1980-96 1999, [Ph.D. thesis], Faculty of Health Sciences, Southern Denmark.
5. Hoek M.R., Christensen H., Hellenbrand W., Stefanoff P., Howitz M., Stuart J.M. Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review. Epidemiol Infect 2008 Nov, 136(11):1441-1447.
6. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011 Jul, 11(7):969-985.
7. O'Ryan M., Stoddard J., Toneatto D., Wassil J., Dull P.M. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs 2014 Jan, 74(1):15-30.
8. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007 Nov, 3(6):290-294.
9. Nissen M.D., Marshall H.S., Richmond P.C., Jiang Q., Harris S.L., Jones T.R., et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013, 32(4):364-371.
10. ® meningococcal B vaccine in the UK 2013, Available at:, [accessed on 03.07.14]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/252859/JCVI_MenB_Update.pdf.
11. Plikaytis B.D., Stella M., Boccadifuoco G., DeTora L.M., Agnusdei M., Santini L., et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19(10):1609-1617.
12. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107(45):19490-19495.
13. Davison K.L., Andrews N., White J.M., Ramsay M.E., Crowcroft N.S., Rushdy A.A., et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?. Arch Dis Child 2004, 89(3):256-260.
14. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13(5):416-425.
15. Frosi G., Biolchi A., Sapio M.L., Rigat F., Gilchrist S., Lucidarme J., et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013, 31(43):4968-4974.
16. Ladhani S.N., Flood J.S., Ramsay M.E., Campbell H., Gray S.J., Kaczmarski E.B., et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012, 30(24):3710-3716.
17. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):617-624.
18. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
19. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
20. Brunelli B., Del T.E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011, 29(5):1072-1081.
21. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29(11):e71-e79.
22. Christensen H., Hickman M., Edmunds W.J., Trotter C.L. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013 May 28, 31(23):2638-2646.
23. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007 Oct 1, 166(7):817-823.
24. McIntyre P.B., O'Brien K.L., Greenwood B., van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012 Nov 10, 380(9854):1703-1711.
25. Read R.C., Baxter D., Chadwick D.R., Faust S.N., Finn A., Gordon S.B., et al. Impact of Quadrivalent Conjugate (MenACWY- CRM) and Serogroup B (4CMenB) Meningococcal Vaccines on Meningococcal Carriage in English University Students [ABSTRACT] November 2013, 5-6. Meningitis Research Foundation Conference, London, Accessed: 01 August 2014. http://www.meningitis.org/conference2013.
26. Okike I.O., Ribeiro S., Ramsay M.E., Heath P.T., Sharland M., Ladhani S.N. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study. Lancet Infect Dis 2014 Apr, 14(4):301-307.
27. Fraser A., Gafter-Gvili A., Paul M., Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2006, 4:CD004785.
28. Stuart J.M., Cartwright K.A., Robinson P.M., Noah N.D. Does eradication of meningococcal carriage in household contacts prevent secondary cases of meningococcal disease?. BMJ 1989 Mar 4, 298(6673):569-570.
29. Dale A.P., Read R.C. Genetic susceptibility to meningococcal infection. Expert Rev Anti Infect Ther 2013 Feb, 11(2):187-199.